Phase I Studies

News Phase I Studies

• CureVac Receives Regulatory Approval to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate
  

  CureVac AG announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and Bel more

• CureVac enters clinical phase with mRNA vaccine

  CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the initiation of its Phase I dose-escalation clinical trial with the novel mRNA-based rabies vaccine, CV7202. This is the first-in-human clinical trial of CureVac’s naturally optimized more

• Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

  Galapagos NV and MorphoSys AG announced the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C. This bridging study is a parallel-design Phase 1 clinical trial conducted in two parts. Part 1 is a single center, ran more